Shopping Cart
Remove All
Your shopping cart is currently empty
Epsilon-V1-2
😃Good
Catalog No. T35827Cas No. 182683-50-7
Alias ε-V1-2, Protein Kinase Cɛ Inhibitor Peptide, PKCε Inhibitor Peptide, ɛV1-2, EAVSLKPT
Epsilon-V1-2 has been extensively investigated for its function as a PKC epsilon (PKCε) inhibitor. Epsilon-V1-2 has been widely applied in studies addressing ovarian aging, apoptosis in human granulosa cells, cerebral ischemia-reperfusion injury, brain development, hepatocyte insulin signaling, and neuronal cell death under ischemic conditions. Epsilon-V1-2 has been shown to effectively reduce PKCε activity, thereby enabling detailed exploration of regulatory pathways involving mitochondrial dynamics, calcium overload, AKT activation, brain atrophy, insulin resistance, and ferroptosis. Epsilon-V1-2 demonstrates notable therapeutic relevance in models of stroke, SHORT syndrome, hepatic steatosis, and brain injury, supporting its continued evaluation as a potential pharmacological agent across multiple disease contexts.
Epsilon-V1-2
😃Good
Purity: 97.09%
Catalog No. T35827Alias ε-V1-2, Protein Kinase Cɛ Inhibitor Peptide, PKCε Inhibitor Peptide, ɛV1-2, EAVSLKPTCas No. 182683-50-7
Epsilon-V1-2 has been extensively investigated for its function as a PKC epsilon (PKCε) inhibitor. Epsilon-V1-2 has been widely applied in studies addressing ovarian aging, apoptosis in human granulosa cells, cerebral ischemia-reperfusion injury, brain development, hepatocyte insulin signaling, and neuronal cell death under ischemic conditions. Epsilon-V1-2 has been shown to effectively reduce PKCε activity, thereby enabling detailed exploration of regulatory pathways involving mitochondrial dynamics, calcium overload, AKT activation, brain atrophy, insulin resistance, and ferroptosis. Epsilon-V1-2 demonstrates notable therapeutic relevance in models of stroke, SHORT syndrome, hepatic steatosis, and brain injury, supporting its continued evaluation as a potential pharmacological agent across multiple disease contexts.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 500 μg | $43 | - | In Stock | |
| 1 mg | $61 | - | In Stock | |
| 5 mg | $147 | - | In Stock | |
| 10 mg | $263 | - | In Stock | |
| 25 mg | $529 | - | In Stock | |
| 50 mg | $753 | - | In Stock | |
| 100 mg | $987 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:97.09%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Epsilon-V1-2 has been extensively investigated for its function as a PKC epsilon (PKCε) inhibitor. Epsilon-V1-2 has been widely applied in studies addressing ovarian aging, apoptosis in human granulosa cells, cerebral ischemia-reperfusion injury, brain development, hepatocyte insulin signaling, and neuronal cell death under ischemic conditions. Epsilon-V1-2 has been shown to effectively reduce PKCε activity, thereby enabling detailed exploration of regulatory pathways involving mitochondrial dynamics, calcium overload, AKT activation, brain atrophy, insulin resistance, and ferroptosis. Epsilon-V1-2 demonstrates notable therapeutic relevance in models of stroke, SHORT syndrome, hepatic steatosis, and brain injury, supporting its continued evaluation as a potential pharmacological agent across multiple disease contexts. |
| In vitro | Epsilon-V1-2 (1 μM, 24 hours) significantly inhibits OA-induced Cx43 Ser368 phosphorylation and protects myocardial gap junctions from OA-induced disruption [2]. |
| In vivo | Epsilon-V1-2 (20 mg/kg/day, subcutaneously implanted with 0.1 mL osmotic pump, administered daily for 4 weeks) significantly improved the beating score of transplanted FVB mouse hearts in C57BL/6J mice [3]. |
| Synonyms | ε-V1-2, Protein Kinase Cɛ Inhibitor Peptide, PKCε Inhibitor Peptide, ɛV1-2, EAVSLKPT |
| Molecular Weight | 843.98 |
| Formula | C37H65N9O13 |
| Cas No. | 182683-50-7 |
| Smiles | C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CCC(O)=O)N)=O)C)=O)[C@H](C)C)=O)CO)=O)CC(C)C)=O)CCCCN)(=O)N1[C@H](C(N[C@@H]([C@@H](C)O)C(O)=O)=O)CCC1 |
| Sequence | H-Glu-Ala-Val-Ser-Leu-Lys-Pro-Thr-OH |
| Sequence Short | EAVSLKPT |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100.00 mg/mL (118.49 mM), Sonication is recommended. H2O: ≥ 80 mg/mL, Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Epsilon-V1-2 | purchase Epsilon-V1-2 | Epsilon-V1-2 cost | order Epsilon-V1-2 | Epsilon-V1-2 chemical structure | Epsilon-V1-2 in vivo | Epsilon-V1-2 in vitro | Epsilon-V1-2 formula | Epsilon-V1-2 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.